Tharimmune Inc(THAR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.91 | Insider Own | 19.46% | Shs Outstand | 39.5M | Perf Week | 8.47% |
| Market Cap | 0.19B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 31.8M | Perf Month | 60.14% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | - | Inst Own | 18.15% | Short Float | 8.09% | Perf Quarter | 57.48% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 35.08% | Short Ratio | 3.33 | Perf Half Y | 251.11% |
| Sales | 0.00B | P/B | 5.55 | EPS next 5Y | - | ROA | -159.36% | Short Interest | 2.58M | Perf YTD | 56.44% |
| Book/sh | 0.85 | P/C | 24.62 | EPS past 3/5Y | 49.44% 29.89% | ROE | -225.01% | 52W High | -47.8% ($9.08) | Perf Year | 149.47% |
| Cash/sh | 0.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -167.66% | 52W Low | 397.9% ($0.95) | Perf 3Y | -99.18% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 64.2% | Gross Margin | - | Volatility(W/M) | 11.08% 12.68% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.98 | EPS Q/Q | 86.28% | Profit Margin | - | RSI (14) | 61.16 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.98 | Sales Q/Q | - | SMA20 | 14.99% ($4.12) | Beta | 1.47 | Target Price | $5 |
| Payout | - | Debt/Eq | 0.03 | Earnings | - | SMA50 | 44.62% ($3.28) | Rel Volume | 0.81 | Prev Close | $4.48 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 81.07% ($2.62) | Avg Volume(3M) | 0.77M | Price | $4.74 |
| IPO | 2022/1/12 | Option/Short | No/Yes | Trades | 3948 | Volume | 624,753 | Change | 5.8% |
🧬 Tharimmune (THAR) is a small biopharmaceutical company dedicated to developing innovative, clinical-stage targeted therapies. The company seeks to deeply investigate the underlying causes of intractable immune disorders and rare liver diseases—conditions that currently lack definitive treatments—and to deliver advanced medical benefits to patients.
Over the past 1 year, roughly in the middle
48% below its 1-year high.
Traded about as much as usual. That is 81% of its average volume.
THAR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be -99.2%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.1%.
Tap to view numbers
It ranks #303 of 598 in the industry
Based on market cap of $187M.
FAQ
What kind of company is THAR?
THAR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of THAR?
The market cap of THAR is approximately $187M, ranking 4,098 within its sector.
What is the 52-week high and low for THAR?
THAR has recorded a 52-week high of $9.08 and a low of $0.95.
